

Gene Therapy On Cardiovascular Disease Industry Research Report 2023

<https://marketpublishers.com/r/GB9EF12ABE2FEN.html>

Date: August 2023

Pages: 91

Price: US\$ 2,950.00 (Single User License)

ID: GB9EF12ABE2FEN

Abstracts

Gene therapy is an experimental technique that uses genes to treat or prevent disease. In the future, this technique may allow doctors to treat a disorder by inserting a gene into a patient's cells instead of using drugs or surgery.

Although several conventional small-molecule treatments are available for common cardiovascular problems, gene therapy is a potential treatment option for acquired and inherited cardiovascular diseases that remain with unmet clinical needs.

Highlights

The global Gene Therapy On Cardiovascular Disease market is projected to reach US\$ million by 2029 from an estimated US\$ million in 2023, at a CAGR of % during 2024 and 2029.

Global key players of Gene Therapy On Cardiovascular Disease include Biogen, Novartis, Gilead Sciences, Sarepta Therapeutics, Alnylam Pharmaceuticals and Amgen, etc. Top three players occupy for a share about 76%. In terms of product, Non-Viral Gene Therapy is the largest segment, with a share over 100%. In terms of application, Vascular Disease is the largest market, with a share over 100%.

Report Scope

This report aims to provide a comprehensive presentation of the global market for Gene Therapy On Cardiovascular Disease, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business

decisions regarding Gene Therapy On Cardiovascular Disease.

The Gene Therapy On Cardiovascular Disease market size, estimations, and forecasts are provided in terms of and revenue (\$ millions), considering 2022 as the base year, with history and forecast data for the period from 2018 to 2029. This report segments the global Gene Therapy On Cardiovascular Disease market comprehensively. Regional market sizes, concerning products by types, by application, and by players, are also provided. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.

For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.

The report will help the Gene Therapy On Cardiovascular Disease companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, product type, application, and regions.

Key Companies & Market Share Insights

In this section, the readers will gain an understanding of the key players competing. This report has studied the key growth strategies, such as innovative trends and developments, intensification of product portfolio, mergers and acquisitions, collaborations, new product innovation, and geographical expansion, undertaken by these participants to maintain their presence. Apart from business strategies, the study includes current developments and key financials. The readers will also get access to the data related to global revenue by companies for the period 2017-2022. This all-inclusive report will certainly serve the clients to stay updated and make effective decisions in their businesses. Some of the prominent players reviewed in the research report include:

Biogen

Novartis

Gilead Sciences

Sarepta Therapeutics

Alnylam Pharmaceuticals

Amgen

Spark Therapeutics

Akcea Therapeutics

bluebird bio

Sunway Biotech

SIBIONO

AnGes

Orchard Therapeutics

Human Stem Cells Institute

Product Type Insights

Global markets are presented by Gene Therapy On Cardiovascular Disease type, along with growth forecasts through 2029. Estimates on revenue are based on the price in the supply chain at which the Gene Therapy On Cardiovascular Disease are procured by the companies.

This report has studied every segment and provided the market size using historical data. They have also talked about the growth opportunities that the segment may pose in the future. This study bestows revenue data by type, and during the historical period (2018-2023) and forecast period (2024-2029).

Gene Therapy On Cardiovascular Disease segment by Type

Viral Gene Therapy

Non-Viral Gene Therapy

Application Insights

This report has provided the market size (revenue data) by application, during the historical period (2018-2023) and forecast period (2024-2029).

This report also outlines the market trends of each segment and consumer behaviors impacting the Gene Therapy On Cardiovascular Disease market and what implications these may have on the industry's future. This report can help to understand the relevant market and consumer trends that are driving the Gene Therapy On Cardiovascular Disease market.

Gene Therapy On Cardiovascular Disease Segment by Application

Heart Disease

Vascular Disease

Regional Outlook

This section of the report provides key insights regarding various regions and the key players operating in each region. Economic, social, environmental, technological, and political factors have been taken into consideration while assessing the growth of the particular region/country. The readers will also get their hands on the revenue data of each region and country for the period 2018-2029.

The market has been segmented into various major geographies, including North America, Europe, Asia-Pacific, South America, Middle East & Africa. Detailed analysis of major countries such as the USA, Germany, the U.K., Italy, France, China, Japan, South Korea, Southeast Asia, and India will be covered within the regional segment. For market estimates, data are going to be provided for 2022 because of the base year, with estimates for 2023 and forecast revenue for 2029.

North America

United States

Canada

Europe

Germany

France

UK

Italy

Russia

Nordic Countries

Rest of Europe

Asia-Pacific

China

Japan

South Korea

Southeast Asia

India

Australia

Rest of Asia

Latin America

Mexico

Brazil

Rest of Latin America

Middle East & Africa

Turkey

Saudi Arabia

UAE

Rest of MEA

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

COVID-19 and Russia-Ukraine War Influence Analysis

The readers in the section will understand how the Gene Therapy On Cardiovascular Disease market scenario changed across the globe during the pandemic, post-pandemic and Russia-Ukraine War. The study is done keeping in view the changes in aspects such as demand, consumption, transportation, consumer behavior, supply chain management. The industry experts have also highlighted the key factors that will help create opportunities for players and stabilize the overall industry in the years to come.

Reasons to Buy This Report

This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Gene Therapy On Cardiovascular Disease market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development,

operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

This report will help stakeholders to understand the global industry status and trends of Gene Therapy On Cardiovascular Disease and provides them with information on key market drivers, restraints, challenges, and opportunities.

This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

This report stays updated with novel technology integration, features, and the latest developments in the market

This report helps stakeholders to understand the COVID-19 and Russia-Ukraine War Influence on the Gene Therapy On Cardiovascular Disease industry.

This report helps stakeholders to gain insights into which regions to target globally

This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Gene Therapy On Cardiovascular Disease.

This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Core Chapters

Chapter 1: Research objectives, research methods, data sources, data cross-validation;

Chapter 2: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 3: Provides the analysis of various market segments product types, covering the market size and development potential of each market segment, to help readers find

the blue ocean market in different market segments.

Chapter 4: Provides the analysis of various market segments application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 5: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.

Chapter 6: Detailed analysis of Gene Therapy On Cardiovascular Disease companies' competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 7, 8, 9, 10, 11: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.

Chapter 12: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 13: The main points and conclusions of the report.

Contents

1 PREFACE

- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
 - 1.5.1 Secondary Sources
 - 1.5.2 Primary Sources

2 MARKET OVERVIEW

- 2.1 Product Definition
- 2.2 Gene Therapy On Cardiovascular Disease by Type
 - 2.2.1 Market Value Comparison by Type (2018 VS 2022 VS 2029)
 - 2.2.2 Viral Gene Therapy
 - 2.2.3 Non-Viral Gene Therapy
- 2.3 Gene Therapy On Cardiovascular Disease by Application
 - 2.3.1 Market Value Comparison by Application (2018 VS 2022 VS 2029)
 - 2.3.2 Heart Disease
 - 2.3.3 Vascular Disease
- 2.4 Assumptions and Limitations

3 GENE THERAPY ON CARDIOVASCULAR DISEASE BREAKDOWN DATA BY TYPE

- 3.1 Global Gene Therapy On Cardiovascular Disease Historic Market Size by Type (2018-2023)
- 3.2 Global Gene Therapy On Cardiovascular Disease Forecasted Market Size by Type (2023-2028)

4 GENE THERAPY ON CARDIOVASCULAR DISEASE BREAKDOWN DATA BY APPLICATION

- 4.1 Global Gene Therapy On Cardiovascular Disease Historic Market Size by Application (2018-2023)
- 4.2 Global Gene Therapy On Cardiovascular Disease Forecasted Market Size by

Application (2018-2023)

5 GLOBAL GROWTH TRENDS

5.1 Global Gene Therapy On Cardiovascular Disease Market Perspective (2018-2029)

5.2 Global Gene Therapy On Cardiovascular Disease Growth Trends by Region

5.2.1 Global Gene Therapy On Cardiovascular Disease Market Size by Region: 2018 VS 2022 VS 2029

5.2.2 Gene Therapy On Cardiovascular Disease Historic Market Size by Region (2018-2023)

5.2.3 Gene Therapy On Cardiovascular Disease Forecasted Market Size by Region (2024-2029)

5.3 Gene Therapy On Cardiovascular Disease Market Dynamics

5.3.1 Gene Therapy On Cardiovascular Disease Industry Trends

5.3.2 Gene Therapy On Cardiovascular Disease Market Drivers

5.3.3 Gene Therapy On Cardiovascular Disease Market Challenges

5.3.4 Gene Therapy On Cardiovascular Disease Market Restraints

6 MARKET COMPETITIVE LANDSCAPE BY PLAYERS

6.1 Global Top Gene Therapy On Cardiovascular Disease Players by Revenue

6.1.1 Global Top Gene Therapy On Cardiovascular Disease Players by Revenue (2018-2023)

6.1.2 Global Gene Therapy On Cardiovascular Disease Revenue Market Share by Players (2018-2023)

6.2 Global Gene Therapy On Cardiovascular Disease Industry Players Ranking, 2021 VS 2022 VS 2023

6.3 Global Key Players of Gene Therapy On Cardiovascular Disease Head office and Area Served

6.4 Global Gene Therapy On Cardiovascular Disease Players, Product Type & Application

6.5 Global Gene Therapy On Cardiovascular Disease Players, Date of Enter into This Industry

6.6 Global Gene Therapy On Cardiovascular Disease Market CR5 and HHI

6.7 Global Players Mergers & Acquisition

7 NORTH AMERICA

7.1 North America Gene Therapy On Cardiovascular Disease Market Size (2018-2029)

7.2 North America Gene Therapy On Cardiovascular Disease Market Growth Rate by Country: 2018 VS 2022 VS 2029

7.3 North America Gene Therapy On Cardiovascular Disease Market Size by Country (2018-2023)

7.4 North America Gene Therapy On Cardiovascular Disease Market Size by Country (2024-2029)

7.5 United States

7.6 Canada

8 EUROPE

8.1 Europe Gene Therapy On Cardiovascular Disease Market Size (2018-2029)

8.2 Europe Gene Therapy On Cardiovascular Disease Market Growth Rate by Country: 2018 VS 2022 VS 2029

8.3 Europe Gene Therapy On Cardiovascular Disease Market Size by Country (2018-2023)

8.4 Europe Gene Therapy On Cardiovascular Disease Market Size by Country (2024-2029)

7.4 Germany

7.5 France

7.6 U.K.

7.7 Italy

7.8 Russia

7.9 Nordic Countries

9 ASIA-PACIFIC

9.1 Asia-Pacific Gene Therapy On Cardiovascular Disease Market Size (2018-2029)

9.2 Asia-Pacific Gene Therapy On Cardiovascular Disease Market Growth Rate by Country: 2018 VS 2022 VS 2029

9.3 Asia-Pacific Gene Therapy On Cardiovascular Disease Market Size by Country (2018-2023)

9.4 Asia-Pacific Gene Therapy On Cardiovascular Disease Market Size by Country (2024-2029)

8.4 China

8.5 Japan

8.6 South Korea

8.7 Southeast Asia

8.8 India

8.9 Australia

10 LATIN AMERICA

10.1 Latin America Gene Therapy On Cardiovascular Disease Market Size (2018-2029)

10.2 Latin America Gene Therapy On Cardiovascular Disease Market Growth Rate by Country: 2018 VS 2022 VS 2029

10.3 Latin America Gene Therapy On Cardiovascular Disease Market Size by Country (2018-2023)

10.4 Latin America Gene Therapy On Cardiovascular Disease Market Size by Country (2024-2029)

9.4 Mexico

9.5 Brazil

11 MIDDLE EAST & AFRICA

11.1 Middle East & Africa Gene Therapy On Cardiovascular Disease Market Size (2018-2029)

11.2 Middle East & Africa Gene Therapy On Cardiovascular Disease Market Growth Rate by Country: 2018 VS 2022 VS 2029

11.3 Middle East & Africa Gene Therapy On Cardiovascular Disease Market Size by Country (2018-2023)

11.4 Middle East & Africa Gene Therapy On Cardiovascular Disease Market Size by Country (2024-2029)

10.4 Turkey

10.5 Saudi Arabia

10.6 UAE

12 PLAYERS PROFILED

11.1 Biogen

11.1.1 Biogen Company Detail

11.1.2 Biogen Business Overview

11.1.3 Biogen Gene Therapy On Cardiovascular Disease Introduction

11.1.4 Biogen Revenue in Gene Therapy On Cardiovascular Disease Business (2017-2022)

11.1.5 Biogen Recent Development

11.2 Novartis

11.2.1 Novartis Company Detail

- 11.2.2 Novartis Business Overview
- 11.2.3 Novartis Gene Therapy On Cardiovascular Disease Introduction
- 11.2.4 Novartis Revenue in Gene Therapy On Cardiovascular Disease Business (2017-2022)
- 11.2.5 Novartis Recent Development
- 11.3 Gilead Sciences
 - 11.3.1 Gilead Sciences Company Detail
 - 11.3.2 Gilead Sciences Business Overview
 - 11.3.3 Gilead Sciences Gene Therapy On Cardiovascular Disease Introduction
 - 11.3.4 Gilead Sciences Revenue in Gene Therapy On Cardiovascular Disease Business (2017-2022)
 - 11.3.5 Gilead Sciences Recent Development
- 11.4 Sarepta Therapeutics
 - 11.4.1 Sarepta Therapeutics Company Detail
 - 11.4.2 Sarepta Therapeutics Business Overview
 - 11.4.3 Sarepta Therapeutics Gene Therapy On Cardiovascular Disease Introduction
 - 11.4.4 Sarepta Therapeutics Revenue in Gene Therapy On Cardiovascular Disease Business (2017-2022)
 - 11.4.5 Sarepta Therapeutics Recent Development
- 11.5 Alnylam Pharmaceuticals
 - 11.5.1 Alnylam Pharmaceuticals Company Detail
 - 11.5.2 Alnylam Pharmaceuticals Business Overview
 - 11.5.3 Alnylam Pharmaceuticals Gene Therapy On Cardiovascular Disease Introduction
 - 11.5.4 Alnylam Pharmaceuticals Revenue in Gene Therapy On Cardiovascular Disease Business (2017-2022)
 - 11.5.5 Alnylam Pharmaceuticals Recent Development
- 11.6 Amgen
 - 11.6.1 Amgen Company Detail
 - 11.6.2 Amgen Business Overview
 - 11.6.3 Amgen Gene Therapy On Cardiovascular Disease Introduction
 - 11.6.4 Amgen Revenue in Gene Therapy On Cardiovascular Disease Business (2017-2022)
 - 11.6.5 Amgen Recent Development
- 11.7 Spark Therapeutics
 - 11.7.1 Spark Therapeutics Company Detail
 - 11.7.2 Spark Therapeutics Business Overview
 - 11.7.3 Spark Therapeutics Gene Therapy On Cardiovascular Disease Introduction
 - 11.7.4 Spark Therapeutics Revenue in Gene Therapy On Cardiovascular Disease

Business (2017-2022)

11.7.5 Spark Therapeutics Recent Development

11.8 Akcea Therapeutics

11.8.1 Akcea Therapeutics Company Detail

11.8.2 Akcea Therapeutics Business Overview

11.8.3 Akcea Therapeutics Gene Therapy On Cardiovascular Disease Introduction

11.8.4 Akcea Therapeutics Revenue in Gene Therapy On Cardiovascular Disease

Business (2017-2022)

11.8.5 Akcea Therapeutics Recent Development

11.9 bluebird bio

11.9.1 bluebird bio Company Detail

11.9.2 bluebird bio Business Overview

11.9.3 bluebird bio Gene Therapy On Cardiovascular Disease Introduction

11.9.4 bluebird bio Revenue in Gene Therapy On Cardiovascular Disease Business

(2017-2022)

11.9.5 bluebird bio Recent Development

11.10 Sunway Biotech

11.10.1 Sunway Biotech Company Detail

11.10.2 Sunway Biotech Business Overview

11.10.3 Sunway Biotech Gene Therapy On Cardiovascular Disease Introduction

11.10.4 Sunway Biotech Revenue in Gene Therapy On Cardiovascular Disease

Business (2017-2022)

11.10.5 Sunway Biotech Recent Development

11.11 SIBIONO

11.11.1 SIBIONO Company Detail

11.11.2 SIBIONO Business Overview

11.11.3 SIBIONO Gene Therapy On Cardiovascular Disease Introduction

11.11.4 SIBIONO Revenue in Gene Therapy On Cardiovascular Disease Business

(2017-2022)

11.11.5 SIBIONO Recent Development

11.12 AnGes

11.12.1 AnGes Company Detail

11.12.2 AnGes Business Overview

11.12.3 AnGes Gene Therapy On Cardiovascular Disease Introduction

11.12.4 AnGes Revenue in Gene Therapy On Cardiovascular Disease Business

(2017-2022)

11.12.5 AnGes Recent Development

11.13 Orchard Therapeutics

11.13.1 Orchard Therapeutics Company Detail

- 11.13.2 Orchard Therapeutics Business Overview
- 11.13.3 Orchard Therapeutics Gene Therapy On Cardiovascular Disease Introduction
- 11.13.4 Orchard Therapeutics Revenue in Gene Therapy On Cardiovascular Disease Business (2017-2022)
- 11.13.5 Orchard Therapeutics Recent Development
- 11.14 Human Stem Cells Institute
 - 11.14.1 Human Stem Cells Institute Company Detail
 - 11.14.2 Human Stem Cells Institute Business Overview
 - 11.14.3 Human Stem Cells Institute Gene Therapy On Cardiovascular Disease Introduction
 - 11.14.4 Human Stem Cells Institute Revenue in Gene Therapy On Cardiovascular Disease Business (2017-2022)
 - 11.14.5 Human Stem Cells Institute Recent Development

13 REPORT CONCLUSION

14 DISCLAIMER

List Of Tables

LIST OF TABLES

Table 1. Secondary Sources

Table 2. Primary Sources

Table 3. Market Value Comparison by Type (2018 VS 2022 VS 2029) & (US\$ Million)

Table 4. Market Value Comparison by Application (2018 VS 2022 VS 2029) & (US\$ Million)

Table 5. Global Gene Therapy On Cardiovascular Disease Market Size by Type (2018-2023) & (US\$ Million)

Table 6. Global Gene Therapy On Cardiovascular Disease Revenue Market Share by Type (2018-2023)

Table 7. Global Gene Therapy On Cardiovascular Disease Forecasted Market Size by Type (2024-2029) & (US\$ Million)

Table 8. Global Gene Therapy On Cardiovascular Disease Revenue Market Share by Type (2024-2029)

Table 9. Global Gene Therapy On Cardiovascular Disease Market Size by Application (2018-2023) & (US\$ Million)

Table 10. Global Gene Therapy On Cardiovascular Disease Revenue Market Share by Application (2018-2023)

Table 11. Global Gene Therapy On Cardiovascular Disease Forecasted Market Size by Application (2024-2029) & (US\$ Million)

Table 12. Global Gene Therapy On Cardiovascular Disease Revenue Market Share by Application (2024-2029)

Table 13. Global Gene Therapy On Cardiovascular Disease Market Size by Region (US\$ Million): 2018 VS 2022 VS 2029

Table 14. Global Gene Therapy On Cardiovascular Disease Market Size by Region (2018-2023) & (US\$ Million)

Table 15. Global Gene Therapy On Cardiovascular Disease Market Share by Region (2018-2023)

Table 16. Global Gene Therapy On Cardiovascular Disease Forecasted Market Size by Region (2024-2029) & (US\$ Million)

Table 17. Global Gene Therapy On Cardiovascular Disease Market Share by Region (2024-2029)

Table 18. Gene Therapy On Cardiovascular Disease Market Trends

Table 19. Gene Therapy On Cardiovascular Disease Market Drivers

Table 20. Gene Therapy On Cardiovascular Disease Market Challenges

Table 21. Gene Therapy On Cardiovascular Disease Market Restraints

Table 22. Global Top Gene Therapy On Cardiovascular Disease Manufacturers by Revenue (US\$ Million) & (2018-2023)

Table 23. Global Gene Therapy On Cardiovascular Disease Revenue Market Share by Manufacturers (2018-2023)

Table 24. Global Gene Therapy On Cardiovascular Disease Industry Manufacturers Ranking, 2021 VS 2022 VS 2023

Table 25. Global Key Players of Gene Therapy On Cardiovascular Disease, Headquarters and Area Served

Table 26. Global Gene Therapy On Cardiovascular Disease Manufacturers, Product Type & Application

Table 27. Global Manufacturers Market Concentration Ratio (CR5 and HHI)

Table 28. Global Gene Therapy On Cardiovascular Disease by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2022)

Table 29. Manufacturers Mergers & Acquisitions, Expansion Plans

Table 30. North America Gene Therapy On Cardiovascular Disease Market Growth Rate by Country: 2018 VS 2022 VS 2029 (US\$ Million)

Table 31. North America Gene Therapy On Cardiovascular Disease Market Size by Country (2018-2023) & (US\$ Million)

Table 32. North America Gene Therapy On Cardiovascular Disease Market Size by Country (2024-2029) & (US\$ Million)

Table 33. Europe Gene Therapy On Cardiovascular Disease Market Growth Rate by Country: 2018 VS 2022 VS 2029 (US\$ Million)

Table 34. Europe Gene Therapy On Cardiovascular Disease Market Size by Country (2018-2023) & (US\$ Million)

Table 35. Europe Gene Therapy On Cardiovascular Disease Market Size by Country (2024-2029) & (US\$ Million)

Table 36. Asia-Pacific Gene Therapy On Cardiovascular Disease Market Growth Rate by Country: 2018 VS 2022 VS 2029 (US\$ Million)

Table 37. Asia-Pacific Gene Therapy On Cardiovascular Disease Market Size by Country (2018-2023) & (US\$ Million)

Table 38. Asia-Pacific Gene Therapy On Cardiovascular Disease Market Size by Country (2024-2029) & (US\$ Million)

Table 39. Latin America Gene Therapy On Cardiovascular Disease Market Growth Rate by Country: 2018 VS 2022 VS 2029 (US\$ Million)

Table 40. Latin America Gene Therapy On Cardiovascular Disease Market Size by Country (2018-2023) & (US\$ Million)

Table 41. Latin America Gene Therapy On Cardiovascular Disease Market Size by Country (2024-2029) & (US\$ Million)

Table 42. Middle East & Africa Gene Therapy On Cardiovascular Disease Market

Growth Rate by Country: 2018 VS 2022 VS 2029 (US\$ Million)

Table 43. Middle East & Africa Gene Therapy On Cardiovascular Disease Market Size by Country (2018-2023) & (US\$ Million)

Table 44. Middle East & Africa Gene Therapy On Cardiovascular Disease Market Size by Country (2024-2029) & (US\$ Million)

Table 45. Biogen Company Detail

Table 46. Biogen Business Overview

Table 47. Biogen Gene Therapy On Cardiovascular Disease Product

Table 48. Biogen Revenue in Gene Therapy On Cardiovascular Disease Business (2017-2022) & (US\$ Million)

Table 49. Biogen Recent Development

Table 50. Novartis Company Detail

Table 51. Novartis Business Overview

Table 52. Novartis Gene Therapy On Cardiovascular Disease Product

Table 53. Novartis Revenue in Gene Therapy On Cardiovascular Disease Business (2017-2022) & (US\$ Million)

Table 54. Novartis Recent Development

Table 55. Gilead Sciences Company Detail

Table 56. Gilead Sciences Business Overview

Table 57. Gilead Sciences Gene Therapy On Cardiovascular Disease Product

Table 58. Gilead Sciences Revenue in Gene Therapy On Cardiovascular Disease Business (2017-2022) & (US\$ Million)

Table 59. Gilead Sciences Recent Development

Table 60. Sarepta Therapeutics Company Detail

Table 61. Sarepta Therapeutics Business Overview

Table 62. Sarepta Therapeutics Gene Therapy On Cardiovascular Disease Product

Table 63. Sarepta Therapeutics Revenue in Gene Therapy On Cardiovascular Disease Business (2017-2022) & (US\$ Million)

Table 64. Sarepta Therapeutics Recent Development

Table 65. Alnylam Pharmaceuticals Company Detail

Table 66. Alnylam Pharmaceuticals Business Overview

Table 67. Alnylam Pharmaceuticals Gene Therapy On Cardiovascular Disease Product

Table 68. Alnylam Pharmaceuticals Revenue in Gene Therapy On Cardiovascular Disease Business (2017-2022) & (US\$ Million)

Table 69. Alnylam Pharmaceuticals Recent Development

Table 70. Amgen Company Detail

Table 71. Amgen Business Overview

Table 72. Amgen Gene Therapy On Cardiovascular Disease Product

Table 73. Amgen Revenue in Gene Therapy On Cardiovascular Disease Business

(2017-2022) & (US\$ Million)

Table 74. Amgen Recent Development

Table 75. Spark Therapeutics Company Detail

Table 76. Spark Therapeutics Business Overview

Table 77. Spark Therapeutics Gene Therapy On Cardiovascular Disease Product

Table 78. Spark Therapeutics Revenue in Gene Therapy On Cardiovascular Disease Business (2017-2022) & (US\$ Million)

Table 79. Spark Therapeutics Recent Development

Table 80. Akcea Therapeutics Company Detail

Table 81. Akcea Therapeutics Business Overview

Table 82. Akcea Therapeutics Gene Therapy On Cardiovascular Disease Product

Table 83. Akcea Therapeutics Revenue in Gene Therapy On Cardiovascular Disease Business (2017-2022) & (US\$ Million)

Table 84. Akcea Therapeutics Recent Development

Table 85. bluebird bio Company Detail

Table 86. bluebird bio Business Overview

Table 87. bluebird bio Gene Therapy On Cardiovascular Disease Product

Table 88. bluebird bio Revenue in Gene Therapy On Cardiovascular Disease Business (2017-2022) & (US\$ Million)

Table 89. bluebird bio Recent Development

Table 90. Sunway Biotech Company Detail

Table 91. Sunway Biotech Business Overview

Table 92. Sunway Biotech Gene Therapy On Cardiovascular Disease Product

Table 93. Sunway Biotech Revenue in Gene Therapy On Cardiovascular Disease Business (2017-2022) & (US\$ Million)

Table 94. Sunway Biotech Recent Development

Table 95. SIBIONO Company Detail

Table 96. SIBIONO Business Overview

Table 97. SIBIONO Gene Therapy On Cardiovascular DiseaseProduct

Table 98. SIBIONO Revenue in Gene Therapy On Cardiovascular Disease Business (2017-2022) & (US\$ Million)

Table 99. SIBIONO Recent Development

Table 100. AnGes Company Detail

Table 101. AnGes Business Overview

Table 102. AnGes Gene Therapy On Cardiovascular DiseaseProduct

Table 103. AnGes Revenue in Gene Therapy On Cardiovascular Disease Business (2017-2022) & (US\$ Million)

Table 104. AnGes Recent Development

Table 105. Orchard Therapeutics Company Detail

- Table 106. Orchard Therapeutics Business Overview
- Table 107. Orchard Therapeutics Gene Therapy On Cardiovascular DiseaseProduct
- Table 108. Orchard Therapeutics Revenue in Gene Therapy On Cardiovascular Disease Business (2017-2022) & (US\$ Million)
- Table 109. Orchard Therapeutics Recent Development
- Table 110. Human Stem Cells Institute Company Detail
- Table 111. Human Stem Cells Institute Business Overview
- Table 112. Human Stem Cells Institute Gene Therapy On Cardiovascular DiseaseProduct
- Table 113. Human Stem Cells Institute Revenue in Gene Therapy On Cardiovascular Disease Business (2017-2022) & (US\$ Million)
- Table 114. Human Stem Cells Institute Recent Development
- Table 115. Biogen Company Information
- Table 116. Biogen Business Overview
- Table 117. Biogen Gene Therapy On Cardiovascular Disease Revenue in Gene Therapy On Cardiovascular Disease Business (2018-2023) & (US\$ Million)
- Table 118. Biogen Revenue in Gene Therapy On Cardiovascular Disease Business (2018-2023) & (US\$ Million) Portfolio
- Table 119. Biogen Recent Development
- Table 120. Novartis Company Information
- Table 121. Novartis Business Overview
- Table 122. Novartis Gene Therapy On Cardiovascular Disease Revenue in Gene Therapy On Cardiovascular Disease Business (2018-2023) & (US\$ Million)
- Table 123. Novartis Revenue in Gene Therapy On Cardiovascular Disease Business (2018-2023) & (US\$ Million) Portfolio
- Table 124. Novartis Recent Development
- Table 125. Gilead Sciences Company Information
- Table 126. Gilead Sciences Business Overview
- Table 127. Gilead Sciences Gene Therapy On Cardiovascular Disease Revenue in Gene Therapy On Cardiovascular Disease Business (2018-2023) & (US\$ Million)
- Table 128. Gilead Sciences Revenue in Gene Therapy On Cardiovascular Disease Business (2018-2023) & (US\$ Million) Portfolio
- Table 129. Gilead Sciences Recent Development
- Table 130. Sarepta Therapeutics Company Information
- Table 131. Sarepta Therapeutics Business Overview
- Table 132. Sarepta Therapeutics Gene Therapy On Cardiovascular Disease Revenue in Gene Therapy On Cardiovascular Disease Business (2018-2023) & (US\$ Million)
- Table 133. Sarepta Therapeutics Revenue in Gene Therapy On Cardiovascular Disease Business (2018-2023) & (US\$ Million) Portfolio

- Table 134. Sarepta Therapeutics Recent Development
- Table 135. Alnylam Pharmaceuticals Company Information
- Table 136. Alnylam Pharmaceuticals Business Overview
- Table 137. Alnylam Pharmaceuticals Gene Therapy On Cardiovascular Disease Revenue in Gene Therapy On Cardiovascular Disease Business (2018-2023) & (US\$ Million)
- Table 138. Alnylam Pharmaceuticals Revenue in Gene Therapy On Cardiovascular Disease Business (2018-2023) & (US\$ Million) Portfolio
- Table 139. Alnylam Pharmaceuticals Recent Development
- Table 140. Amgen Company Information
- Table 141. Amgen Business Overview
- Table 142. Amgen Gene Therapy On Cardiovascular Disease Revenue in Gene Therapy On Cardiovascular Disease Business (2018-2023) & (US\$ Million)
- Table 143. Amgen Revenue in Gene Therapy On Cardiovascular Disease Business (2018-2023) & (US\$ Million) Portfolio
- Table 144. Amgen Recent Development
- Table 145. Spark Therapeutics Company Information
- Table 146. Spark Therapeutics Business Overview
- Table 147. Spark Therapeutics Gene Therapy On Cardiovascular Disease Revenue in Gene Therapy On Cardiovascular Disease Business (2018-2023) & (US\$ Million)
- Table 148. Spark Therapeutics Revenue in Gene Therapy On Cardiovascular Disease Business (2018-2023) & (US\$ Million) Portfolio
- Table 149. Spark Therapeutics Recent Development
- Table 150. Akcea Therapeutics Company Information
- Table 151. Akcea Therapeutics Business Overview
- Table 152. Akcea Therapeutics Gene Therapy On Cardiovascular Disease Revenue in Gene Therapy On Cardiovascular Disease Business (2018-2023) & (US\$ Million)
- Table 153. Akcea Therapeutics Revenue in Gene Therapy On Cardiovascular Disease Business (2018-2023) & (US\$ Million) Portfolio
- Table 154. Akcea Therapeutics Recent Development
- Table 155. bluebird bio Company Information
- Table 156. bluebird bio Business Overview
- Table 157. bluebird bio Gene Therapy On Cardiovascular Disease Revenue in Gene Therapy On Cardiovascular Disease Business (2018-2023) & (US\$ Million)
- Table 158. bluebird bio Revenue in Gene Therapy On Cardiovascular Disease Business (2018-2023) & (US\$ Million) Portfolio
- Table 159. bluebird bio Recent Development
- Table 160. Sunway Biotech Company Information
- Table 161. Sunway Biotech Business Overview

- Table 162. Sunway Biotech Gene Therapy On Cardiovascular Disease Revenue in Gene Therapy On Cardiovascular Disease Business (2018-2023) & (US\$ Million)
- Table 163. Sunway Biotech Revenue in Gene Therapy On Cardiovascular Disease Business (2018-2023) & (US\$ Million) Portfolio
- Table 164. Sunway Biotech Recent Development
- Table 165. SIBIONO Company Information
- Table 166. SIBIONO Business Overview
- Table 167. SIBIONO Gene Therapy On Cardiovascular Disease Revenue in Gene Therapy On Cardiovascular Disease Business (2018-2023) & (US\$ Million)
- Table 168. SIBIONO Revenue in Gene Therapy On Cardiovascular Disease Business (2018-2023) & (US\$ Million) Portfolio
- Table 169. SIBIONO Recent Development
- Table 170. AnGes Company Information
- Table 171. AnGes Business Overview
- Table 172. AnGes Gene Therapy On Cardiovascular Disease Revenue in Gene Therapy On Cardiovascular Disease Business (2018-2023) & (US\$ Million)
- Table 173. AnGes Revenue in Gene Therapy On Cardiovascular Disease Business (2018-2023) & (US\$ Million) Portfolio
- Table 174. AnGes Recent Development
- Table 175. Orchard Therapeutics Company Information
- Table 176. Orchard Therapeutics Business Overview
- Table 177. Orchard Therapeutics Gene Therapy On Cardiovascular Disease Revenue in Gene Therapy On Cardiovascular Disease Business (2018-2023) & (US\$ Million)
- Table 178. Orchard Therapeutics Revenue in Gene Therapy On Cardiovascular Disease Business (2018-2023) & (US\$ Million) Portfolio
- Table 179. Orchard Therapeutics Recent Development
- Table 180. Human Stem Cells Institute Company Information
- Table 181. Human Stem Cells Institute Business Overview
- Table 182. Human Stem Cells Institute Gene Therapy On Cardiovascular Disease Revenue in Gene Therapy On Cardiovascular Disease Business (2018-2023) & (US\$ Million)
- Table 183. Human Stem Cells Institute Revenue in Gene Therapy On Cardiovascular Disease Business (2018-2023) & (US\$ Million) Portfolio
- Table 184. Human Stem Cells Institute Recent Development
- Table 185. Authors List of This Report

List Of Figures

LIST OF FIGURES

Figure 1. Research Methodology

Figure 2. Research Process

Figure 3. Key Executives Interviewed

Figure 4. Gene Therapy On Cardiovascular Disease Product Picture

Figure 5. Global Gene Therapy On Cardiovascular Disease Market Size Comparison by Type (2023-2029) & (US\$ Million)

Figure 6. Global Gene Therapy On Cardiovascular Disease Market Share by Type: 2022 VS 2029

Figure 7. Viral Gene Therapy Product Picture

Figure 8. Non-Viral Gene Therapy Product Picture

Figure 9. Global Gene Therapy On Cardiovascular Disease Market Size by Application (2023-2029) & (US\$ Million)

Figure 10. Global Gene Therapy On Cardiovascular Disease Market Share by Application: 2022 VS 2029

Figure 11. Heart Disease Product Picture

Figure 12. Vascular Disease Product Picture

Figure 13. Global Gene Therapy On Cardiovascular Disease Market Size (US\$ Million), Year-over-Year: 2018-2029

Figure 14. Global Gene Therapy On Cardiovascular Disease Market Size, (US\$ Million), 2018 VS 2022 VS 2029

Figure 15. Global Gene Therapy On Cardiovascular Disease Market Share by Region: 2022 VS 2029

Figure 16. Global Gene Therapy On Cardiovascular Disease Market Share by Players in 2022

Figure 17. Global Gene Therapy On Cardiovascular Disease Players, Date of Enter into This Industry

Figure 18. Global Top 5 and 10 Gene Therapy On Cardiovascular Disease Players Market Share by Revenue in 2022

Figure 19. Players Type (Tier 1, Tier 2, and Tier 3): 2018 VS 2022

Figure 20. North America Gene Therapy On Cardiovascular Disease Market Size YoY Growth (2018-2029) & (US\$ Million)

Figure 21. North America Gene Therapy On Cardiovascular Disease Market Share by Country (2018-2029)

Figure 22. United States Gene Therapy On Cardiovascular Disease Market Size YoY Growth (2018-2029) & (US\$ Million)

Figure 23. Canada Gene Therapy On Cardiovascular Disease Market Size YoY Growth (2018-2029) & (US\$ Million)

Figure 24. Europe Gene Therapy On Cardiovascular Disease Market Size YoY Growth (2018-2029) & (US\$ Million)

Figure 25. Europe Gene Therapy On Cardiovascular Disease Market Share by Country (2018-2029)

Figure 26. Germany Gene Therapy On Cardiovascular Disease Market Size YoY Growth (2018-2029) & (US\$ Million)

Figure 27. France Gene Therapy On Cardiovascular Disease Market Size YoY Growth (2018-2029) & (US\$ Million)

Figure 28. U.K. Gene Therapy On Cardiovascular Disease Market Size YoY Growth (2018-2029) & (US\$ Million)

Figure 29. Italy Gene Therapy On Cardiovascular Disease Market Size YoY Growth (2018-2029) & (US\$ Million)

Figure 30. Russia Gene Therapy On Cardiovascular Disease Market Size YoY Growth (2018-2029) & (US\$ Million)

Figure 31. Nordic Countries Gene Therapy On Cardiovascular Disease Market Size YoY Growth (2018-2029) & (US\$ Million)

Figure 32. Asia-Pacific Gene Therapy On Cardiovascular Disease Market Size YoY Growth (2018-2029) & (US\$ Million)

Figure 33. Asia-Pacific Gene Therapy On Cardiovascular Disease Market Share by Country (2018-2029)

Figure 34. China Gene Therapy On Cardiovascular Disease Market Size YoY Growth (2018-2029) & (US\$ Million)

Figure 35. Japan Gene Therapy On Cardiovascular Disease Market Size YoY Growth (2018-2029) & (US\$ Million)

Figure 36. South Korea Gene Therapy On Cardiovascular Disease Market Size YoY Growth (2018-2029) & (US\$ Million)

Figure 37. Southeast Asia Gene Therapy On Cardiovascular Disease Market Size YoY Growth (2018-2029) & (US\$ Million)

Figure 38. India Gene Therapy On Cardiovascular Disease Market Size YoY Growth (2018-2029) & (US\$ Million)

Figure 39. Australia Gene Therapy On Cardiovascular Disease Market Size YoY Growth (2018-2029) & (US\$ Million)

Figure 40. Latin America Gene Therapy On Cardiovascular Disease Market Size YoY Growth (2018-2029) & (US\$ Million)

Figure 41. Latin America Gene Therapy On Cardiovascular Disease Market Share by Country (2018-2029)

Figure 42. Mexico Gene Therapy On Cardiovascular Disease Market Size YoY Growth

(2018-2029) & (US\$ Million)

Figure 43. Brazil Gene Therapy On Cardiovascular Disease Market Size YoY Growth (2018-2029) & (US\$ Million)

Figure 44. Middle East & Africa Gene Therapy On Cardiovascular Disease Market Size YoY Growth (2018-2029) & (US\$ Million)

Figure 45. Middle East & Africa Gene Therapy On Cardiovascular Disease Market Share by Country (2018-2029)

Figure 46. Turkey Gene Therapy On Cardiovascular Disease Market Size YoY Growth (2018-2029) & (US\$ Million)

Figure 47. Saudi Arabia Gene Therapy On Cardiovascular Disease Market Size YoY Growth (2018-2029) & (US\$ Million)

Figure 48. UAE Gene Therapy On Cardiovascular Disease Market Size YoY Growth (2018-2029) & (US\$ Million)

Figure 49. Biogen Revenue Growth Rate in Gene Therapy On Cardiovascular Disease Business (2018-2023)

Figure 50. Novartis Revenue Growth Rate in Gene Therapy On Cardiovascular Disease Business (2018-2023)

Figure 51. Gilead Sciences Revenue Growth Rate in Gene Therapy On Cardiovascular Disease Business (2018-2023)

Figure 52. Sarepta Therapeutics Revenue Growth Rate in Gene Therapy On Cardiovascular Disease Business (2018-2023)

Figure 53. Alnylam Pharmaceuticals Revenue Growth Rate in Gene Therapy On Cardiovascular Disease Business (2018-2023)

Figure 54. Amgen Revenue Growth Rate in Gene Therapy On Cardiovascular Disease Business (2018-2023)

Figure 55. Spark Therapeutics Revenue Growth Rate in Gene Therapy On Cardiovascular Disease Business (2018-2023)

Figure 56. Akcea Therapeutics Revenue Growth Rate in Gene Therapy On Cardiovascular Disease Business (2018-2023)

Figure 57. bluebird bio Revenue Growth Rate in Gene Therapy On Cardiovascular Disease Business (2018-2023)

Figure 58. Sunway Biotech Revenue Growth Rate in Gene Therapy On Cardiovascular Disease Business (2018-2023)

Figure 59. SIBIONO Revenue Growth Rate in Gene Therapy On Cardiovascular Disease Business (2018-2023)

Figure 60. AnGes Revenue Growth Rate in Gene Therapy On Cardiovascular Disease Business (2018-2023)

Figure 61. Orchard Therapeutics Revenue Growth Rate in Gene Therapy On Cardiovascular Disease Business (2018-2023)

Figure 62. Human Stem Cells Institute Revenue Growth Rate in Gene Therapy On Cardiovascular Disease Business (2018-2023)

I would like to order

Product name: Gene Therapy On Cardiovascular Disease Industry Research Report 2023

Product link: <https://marketpublishers.com/r/GB9EF12ABE2FEN.html>

Price: US\$ 2,950.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/GB9EF12ABE2FEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970